GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Material
Publisher
Person/Organisation
Language
Years
FID
Subjects(RVK)
  • 1
    Online Resource
    Online Resource
    Impact of jet-production data on the next-to-next-to-leading-order determination of HERAPDF2.0 parton distributions
    Springer Science and Business Media LLC ; 2022
    In:  The European Physical Journal C Vol. 82, No. 3 ( 2022-03)
    Details
    In: The European Physical Journal C, Springer Science and Business Media LLC, Vol. 82, No. 3 ( 2022-03)
    Abstract: The HERAPDF2.0 ensemble of parton distribution functions (PDFs) was introduced in 2015. The final stage is presented, a next-to-next-to-leading-order (NNLO) analysis of the HERA data on inclusive deep inelastic ep scattering together with jet data as published by the H1 and ZEUS collaborations. A perturbative QCD fit, simultaneously of $$\alpha _s(M_Z^2)$$ α s ( M Z 2 ) and the PDFs, was performed with the result $$\alpha _s(M_Z^2)= 0.1156 \pm 0.0011~\mathrm{(exp)}~ ^{+0.0001}_{-0.0002}~ \mathrm{(model}$$ α s ( M Z 2 ) = 0.1156 ± 0.0011 ( exp ) - 0.0002 + 0.0001 ( model $$\mathrm{+ parameterisation)}~ \pm 0.0029~\mathrm{(scale)}$$ + parameterisation ) ± 0.0029 ( scale ) . The PDF sets of HERAPDF2.0Jets NNLO were determined with separate fits using two fixed values of $$\alpha _s(M_Z^2)$$ α s ( M Z 2 ) , $$\alpha _s(M_Z^2)=0.1155$$ α s ( M Z 2 ) = 0.1155 and 0.118, since the latter value was already chosen for the published HERAPDF2.0 NNLO analysis based on HERA inclusive DIS data only. The different sets of PDFs are presented, evaluated and compared. The consistency of the PDFs determined with and without the jet data demonstrates the consistency of HERA inclusive and jet-production cross-section data. The inclusion of the jet data reduced the uncertainty on the gluon PDF. Predictions based on the PDFs of HERAPDF2.0Jets NNLO give an excellent description of the jet-production data used as input.
    Type of Medium: Online Resource
    ISSN: 1434-6044 , 1434-6052
    URL: Article
    DOI: 10.1140/epjc/s10052-022-10083-9
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2022
    detail.hit.zdb_id: 1397769-6
    detail.hit.zdb_id: 1459069-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    The Large Hadron–Electron Collider at the HL-LHC
    IOP Publishing ; 2021
    In:  Journal of Physics G: Nuclear and Particle Physics Vol. 48, No. 11 ( 2021-11-01), p. 110501-
    Details
    In: Journal of Physics G: Nuclear and Particle Physics, IOP Publishing, Vol. 48, No. 11 ( 2021-11-01), p. 110501-
    Abstract: The Large Hadron–Electron Collider (LHeC) is designed to move the field of deep inelastic scattering (DIS) to the energy and intensity frontier of particle physics. Exploiting energy-recovery technology, it collides a novel, intense electron beam with a proton or ion beam from the High-Luminosity Large Hadron Collider (HL-LHC). The accelerator and interaction region are designed for concurrent electron–proton and proton–proton operations. This report represents an update to the LHeC’s conceptual design report (CDR), published in 2012. It comprises new results on the parton structure of the proton and heavier nuclei, QCD dynamics, and electroweak and top-quark physics. It is shown how the LHeC will open a new chapter of nuclear particle physics by extending the accessible kinematic range of lepton–nucleus scattering by several orders of magnitude. Due to its enhanced luminosity and large energy and the cleanliness of the final hadronic states, the LHeC has a strong Higgs physics programme and its own discovery potential for new physics. Building on the 2012 CDR, this report contains a detailed updated design for the energy-recovery electron linac (ERL), including a new lattice, magnet and superconducting radio-frequency technology, and further components. Challenges of energy recovery are described, and the lower-energy, high-current, three-turn ERL facility, PERLE at Orsay, is presented, which uses the LHeC characteristics serving as a development facility for the design and operation of the LHeC. An updated detector design is presented corresponding to the acceptance, resolution, and calibration goals that arise from the Higgs and parton-density-function physics programmes. This paper also presents novel results for the Future Circular Collider in electron–hadron (FCC-eh) mode, which utilises the same ERL technology to further extend the reach of DIS to even higher centre-of-mass energies.
    Type of Medium: Online Resource
    ISSN: 0954-3899 , 1361-6471
    URL: Article
    DOI: 10.1088/1361-6471/abf3ba
    RVK:
    UA 4720.G
    Language: Unknown
    Publisher: IOP Publishing
    Publication Date: 2021
    detail.hit.zdb_id: 1472964-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    Polymerized cyclodextrin microparticles for sustained antibiotic delivery in lung infections
    Wiley ; 2024
    In:  Journal of Biomedical Materials Research Part A Vol. 112, No. 8 ( 2024-08), p. 1305-1316
    Details
    In: Journal of Biomedical Materials Research Part A, Wiley, Vol. 112, No. 8 ( 2024-08), p. 1305-1316
    Abstract: Pulmonary infections complicate chronic lung diseases requiring attention to both the pathophysiology and complexity associated with infection management. Patients with cystic fibrosis (CF) struggle with continuous bouts of pulmonary infections, contributing to lung destruction and eventual mortality. Additionally, CF patients struggle with airways that are highly viscous, with accumulated mucus creating optimal environments for bacteria colonization. The unique physiology and altered airway environment provide an ideal niche for bacteria to change their phenotype often becoming resistant to current treatments. Colonization with multiple pathogens at the same time further complicate treatment algorithms, requiring drug combinations that can challenge CF patient tolerance to treatment. The goal of this research initiative was to explore the utilization of a microparticle antibiotic delivery system, which could provide localized and sustained antibiotic dosing. The outcome of this work demonstrates the feasibility of providing efficient localized delivery of antibiotics to manage infection using both preclinical in vitro and in vivo CF infection models. The studies outlined in this manuscript demonstrate the proof‐of‐concept and unique capacity of polymerized cyclodextrin microparticles to provide site‐directed management of pulmonary infections.
    Type of Medium: Online Resource
    ISSN: 1549-3296 , 1552-4965
    URL: Issue
    URL: Article
    DOI: 10.1002/jbm.a.v112.8
    DOI: 10.1002/jbm.a.37680
    Language: English
    Publisher: Wiley
    Publication Date: 2024
    detail.hit.zdb_id: 1477192-5
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    Calculations for deep inelastic scattering using fast interpolation grid techniques at NNLO in QCD and the extraction of $$\alpha _{\mathrm {s}}$$ from HERA data
    Springer Science and Business Media LLC ; 2019
    In:  The European Physical Journal C Vol. 79, No. 10 ( 2019-10)
    Details
    In: The European Physical Journal C, Springer Science and Business Media LLC, Vol. 79, No. 10 ( 2019-10)
    Abstract: The extension of interpolation-grid frameworks for perturbative QCD calculations at next-to-next-to-leading order (NNLO) is presented for deep inelastic scattering (DIS) processes. A fast and flexible evaluation of higher-order predictions for any a posteriori choice of parton distribution functions (PDFs) or value of the strong coupling constant is essential in iterative fitting procedures to extract PDFs and Standard Model parameters as well as for a detailed study of the scale dependence. The APPLfast project, described here, provides a generic interface between the parton-level Monte Carlo program NNLO jet  and both the APPLgrid and fastNLO libraries for the production of interpolation grids at NNLO accuracy. Details of the interface for DIS processes are presented together with the required interpolation grids at NNLO, which are made available. They cover numerous inclusive jet measurements by the H1 and ZEUS experiments at HERA. An extraction of the strong coupling constant is performed as an application of the use of such grids and a best-fit value of $$\alpha _{\mathrm {s}} (M_{{\mathrm {Z}}}) = 0.1170\,(15)_\text {exp}\,(25)_\text {th}$$ α s ( M Z ) = 0.1170 ( 15 ) exp ( 25 ) th is obtained using the HERA inclusive jet cross section data.
    Type of Medium: Online Resource
    ISSN: 1434-6044 , 1434-6052
    URL: Article
    DOI: 10.1140/epjc/s10052-019-7351-x
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2019
    detail.hit.zdb_id: 1397769-6
    detail.hit.zdb_id: 1459069-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    Erratum to: Calculations for deep inelastic scattering using fast interpolation grid techniques at NNLO in QCD and the extraction of $$\alpha _{\mathrm {s}}$$ from HERA data
    Springer Science and Business Media LLC ; 2021
    In:  The European Physical Journal C Vol. 81, No. 10 ( 2021-10)
    Details
    In: The European Physical Journal C, Springer Science and Business Media LLC, Vol. 81, No. 10 ( 2021-10)
    Type of Medium: Online Resource
    ISSN: 1434-6044 , 1434-6052
    URL: Article
    DOI: 10.1140/epjc/s10052-021-09688-3
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2021
    detail.hit.zdb_id: 1397769-6
    detail.hit.zdb_id: 1459069-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 6
    Online Resource
    Online Resource
    Anti-Inflammatory Therapeutic Development and Optimization of Umbilical Cord Tissue Derived Mesenchymal Stem Cells
    OMICS Publishing Group ; 2018
    In:  Journal of Stem Cell Research & Therapy Vol. 08, No. 08 ( 2018)
    Details
    In: Journal of Stem Cell Research & Therapy, OMICS Publishing Group, Vol. 08, No. 08 ( 2018)
    Type of Medium: Online Resource
    ISSN: 2157-7633
    URL: Journal
    URL: Article
    DOI: 10.4172/2157-7633
    DOI: 10.4172/2157-7633.1000435
    Language: Unknown
    Publisher: OMICS Publishing Group
    Publication Date: 2018
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 7
    Online Resource
    Online Resource
    Mesenchymal Stem Cell Soluble Mediators and Cystic Fibrosis
    OMICS Publishing Group ; 2017
    In:  Journal of Stem Cell Research & Therapy Vol. 07, No. 09 ( 2017)
    Details
    In: Journal of Stem Cell Research & Therapy, OMICS Publishing Group, Vol. 07, No. 09 ( 2017)
    Type of Medium: Online Resource
    ISSN: 2157-7633
    URL: Journal
    URL: Article
    DOI: 10.4172/2157-7633
    DOI: 10.4172/2157-7633.1000400
    Language: Unknown
    Publisher: OMICS Publishing Group
    Publication Date: 2017
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 8
    Online Resource
    Online Resource
    Antimicrobial Properties of Mesenchymal Stem Cells: Therapeutic Potential for Cystic Fibrosis Infection, and Treatment
    Hindawi Limited ; 2016
    In:  Stem Cells International Vol. 2016 ( 2016), p. 1-12
    Details
    In: Stem Cells International, Hindawi Limited, Vol. 2016 ( 2016), p. 1-12
    Abstract: Cystic fibrosis (CF) is a genetic disease in which the battle between pulmonary infection and inflammation becomes the major cause of morbidity and mortality. We have previously shown that human MSCs (hMSCs) decrease inflammation and infection in the in vivo murine model of CF. The studies in this paper focus on the specificity of the hMSC antimicrobial effectiveness using Pseudomonas aeruginosa (gram negative bacteria) and Staphylococcus aureus (gram positive bacteria). Our studies show that hMSCs secrete bioactive molecules which are antimicrobial in vitro against Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumonia , impacting the rate of bacterial growth and transition into colony forming units regardless of the pathogen. Further, we show that the hMSCs have the capacity to enhance antibiotic sensitivity, improving the capacity to kill bacteria. We present data which suggests that the antimicrobial effectiveness is associated with the capacity to slow bacterial growth and the ability of the hMSCs to secrete the antimicrobial peptide LL-37. Lastly, our studies demonstrate that the tissue origin of the hMSCs (bone marrow or adipose tissue derived), the presence of functional cystic fibrosis transmembrane conductance regulator (CFTR: human, Cftr : mouse) activity, and response to effector cytokines can impact both hMSC phenotype and antimicrobial potency and efficacy. These studies demonstrate, the unique capacity of the hMSCs to manage different pathogens and the significance of their phenotype in both the antimicrobial and antibiotic enhancing activities.
    Type of Medium: Online Resource
    ISSN: 1687-966X , 1687-9678
    URL: Article
    DOI: 10.1155/2016/5303048
    Language: English
    Publisher: Hindawi Limited
    Publication Date: 2016
    detail.hit.zdb_id: 2573856-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 9
    Online Resource
    Online Resource
    Human Mesenchymal Stem Cell (hMSC) Donor Potency Selection for the “First in Cystic Fibrosis” Phase I Clinical Trial (CEASE-CF)
    MDPI AG ; 2023
    In:  Pharmaceuticals Vol. 16, No. 2 ( 2023-02-01), p. 220-
    Details
    In: Pharmaceuticals, MDPI AG, Vol. 16, No. 2 ( 2023-02-01), p. 220-
    Abstract: Human Mesenchymal Stem Cell (hMSC) immunotherapy has been shown to provide both anti-inflammatory and anti-microbial effectiveness in a variety of diseases. The clinical potency of hMSCs is based upon an initial direct hMSC effect on the pro-inflammatory and anti-microbial pathophysiology as well as sustained potency through orchestrating the host immunity to optimize the resolution of infection and tissue damage. Cystic fibrosis (CF) patients suffer from a lung disease characterized by excessive inflammation and chronic infection as well as a variety of other systemic anomalies associated with the consequences of abnormal cystic fibrosis transmembrane conductance regulator (CFTR) function. The application of hMSC immunotherapy to the CF clinical armamentarium is important even in the era of modulators when patients with an established disease still need anti-inflammatory and anti-microbial therapies. Additionally, people with CF mutations not addressed by current modulator resources need anti-inflammation and anti-infection management. Furthermore, hMSCs possess dynamic therapeutic properties, but the potency of their products is highly variable with respect to their anti-inflammatory and anti-microbial effects. Due to the variability of hMSC products, we utilized standardized in vitro and in vivo models to select hMSC donor preparations with the greatest potential for clinical efficacy. The models that were used recapitulate many of the pathophysiologic outcomes associated with CF. We applied this strategy in pursuit of identifying the optimal donor to utilize for the “First in CF” Phase I clinical trial of hMSCs as an immunotherapy and anti-microbial therapy for people with cystic fibrosis. The hMSCs screened in this study demonstrated significant diversity in antimicrobial and anti-inflammatory function using models which mimic some aspects of CF infection and inflammation. However, the variability in activity between in vitro potency and in vivo effectiveness continues to be refined. Future studies require and in-depth pursuit of hMSC molecular signatures that ultimately predict the capacity of hMSCs to function in the clinical setting.
    Type of Medium: Online Resource
    ISSN: 1424-8247
    URL: Article
    DOI: 10.3390/ph16020220
    Language: English
    Publisher: MDPI AG
    Publication Date: 2023
    detail.hit.zdb_id: 2193542-7
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 10
    Online Resource
    Online Resource
    DataSheet1.pdf
    Frontiers Media SA ; 2021
    In:  Frontiers in Pharmacology Vol. 12 ( 2021-5-13)
    Details
    In: Frontiers in Pharmacology, Frontiers Media SA, Vol. 12 ( 2021-5-13)
    Abstract: In cystic fibrosis (CF), sustained infection and exuberant inflammation results in debilitating and often fatal lung disease. Advancement in CF therapeutics has provided successful treatment regimens for a variety of clinical consequences in CF; however effective means to treat the pulmonary infection and inflammation continues to be problematic. Even with the successful development of small molecule cystic fibrosis transmembrane conductance regulator (CFTR) correctors and potentiators, there is only a modest effect on established infection and inflammation in CF patients. In the pursuit of therapeutics to treat inflammation, the conundrum to address is how to overcome the inflammatory response without jeopardizing the required immunity to manage pathogens and prevent infection. The key therapeutic would have the capacity to dull the inflammatory response, while sustaining the ability to manage infections. Advances in cell-based therapy have opened up the avenue for dynamic and versatile immune interventions that may support this requirement. Cell based therapy has the capacity to augment the patient’s own ability to manage their inflammatory status while at the same time sustaining anti-pathogen immunity. The studies highlighted in this manuscript outline the potential use of cell-based therapy for CF. The data demonstrate that 1) total bone marrow aspirates containing Cftr sufficient hematopoietic and mesenchymal stem cells (hMSCs) provide Cftr deficient mice & gt;50% improvement in survival and improved management of infection and inflammation; 2) myeloid cells can provide sufficient Cftr to provide pre-clinical anti-inflammatory and antimicrobial benefit; 3) hMSCs provide significant improvement in survival and management of infection and inflammation in CF; 4) the combined interaction between macrophages and hMSCs can potentially enhance anti-inflammatory and antimicrobial support through manipulating PPARγ. These data support the development of optimized cell-based therapeutics to enhance CF patient’s own immune repertoire and capacity to maintain the balance between inflammation and pathogen management.
    Type of Medium: Online Resource
    ISSN: 1663-9812
    URL: Article
    URL: Article
    DOI: 10.3389/fphar.2021.573065
    DOI: 10.3389/fphar.2021.573065.s001
    Language: Unknown
    Publisher: Frontiers Media SA
    Publication Date: 2021
    detail.hit.zdb_id: 2587355-6
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...